

Galectin 3 - Pipeline Review, H1 2020

<https://marketpublishers.com/r/G67412ED10EDEN.html>

Date: February 2020

Pages: 81

Price: US\$ 3,500.00 (Single User License)

ID: G67412ED10EDEN

Abstracts

Galectin 3 - Pipeline Review, H1 2020

SUMMARY

Galectin 3 (35 kDa Lectin or Carbohydrate Binding Protein 35 or Galactose Specific Lectin 3 or Galactoside Binding Protein or IgE Binding Protein or Laminin Binding Protein or Mac 2 Antigen or LGALS3) - Galectin-3 is a protein encoded by the LGALS3 gene. It mediates with the alpha-3, beta-1 integrin the stimulation by CSPG4 of endothelial cells migration. It acts as a pre-mRNA splicing factor. It is involved in acute inflammatory responses including neutrophil activation and adhesion, chemoattraction of monocytes macrophages, opsonization of apoptotic neutrophils, and activation of mast cells.

Galectin 3 (35 kDa Lectin or Carbohydrate Binding Protein 35 or Galactose Specific Lectin 3 or Galactoside Binding Protein or IgE Binding Protein or Laminin Binding Protein or Mac 2 Antigen or LGALS3) pipeline Target constitutes close to 16 molecules. The molecules developed by companies in Phase II, Phase I, Preclinical and Discovery stages are 3, 1, 9 and 3 respectively. Report covers products from therapy areas Oncology, Cardiovascular, Gastrointestinal, Respiratory, Undisclosed, Genito Urinary System And Sex Hormones, Immunology and Ophthalmology which include indications Liver Fibrosis, Pulmonary Fibrosis, Unspecified, Breast Cancer, Idiopathic Pulmonary Fibrosis, Myocardial Fibrosis, Non-Alcoholic Steatohepatitis (NASH), Arrhythmias, Atrial Fibrillation, Blood Cancer, Chronic Kidney Disease (Chronic Renal Failure), Congestive Heart Failure (Heart Failure), Head And Neck Cancer Squamous Cell Carcinoma, Inflammation, Keratoconjunctivitis Sicca (Dry Eye), Kidney Fibrosis, Liver Cirrhosis, Metastatic Melanoma, Metastatic Prostate Cancer, Myelofibrosis, Myocardial Infarction, Non-Small Cell Lung Cancer, Ovarian Cancer, Plaque Psoriasis (Psoriasis Vulgaris), Portal Hypertension, Prostate Cancer, Pulmonary Arterial Hypertension, Sarcomas,

Skin Cancer and Venous (Vein) Thrombosis.

The latest report Galectin 3 - Pipeline Review, H1 2020, outlays comprehensive information on the Galectin 3 (35 kDa Lectin or Carbohydrate Binding Protein 35 or Galactose Specific Lectin 3 or Galactoside Binding Protein or IgE Binding Protein or Laminin Binding Protein or Mac 2 Antigen or LGALS3) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Galectin 3 (35 kDa Lectin or Carbohydrate Binding Protein 35 or Galactose Specific Lectin 3 or Galactoside Binding Protein or IgE Binding Protein or Laminin Binding Protein or Mac 2 Antigen or LGALS3) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

The report provides a snapshot of the global therapeutic landscape for Galectin 3 (35 kDa Lectin or Carbohydrate Binding Protein 35 or Galactose Specific Lectin 3 or Galactoside Binding Protein or IgE Binding Protein or Laminin Binding Protein or Mac 2 Antigen or LGALS3)

The report reviews Galectin 3 (35 kDa Lectin or Carbohydrate Binding Protein 35 or Galactose Specific Lectin 3 or Galactoside Binding Protein or IgE Binding Protein or Laminin Binding Protein or Mac 2 Antigen or LGALS3) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which

includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Galectin 3 (35 kDa Lectin or Carbohydrate Binding Protein 35 or Galactose Specific Lectin 3 or Galactoside Binding Protein or IgE Binding Protein or Laminin Binding Protein or Mac 2 Antigen or LGALS3) targeted therapeutics and enlists all their major and minor projects

The report assesses Galectin 3 (35 kDa Lectin or Carbohydrate Binding Protein 35 or Galactose Specific Lectin 3 or Galactoside Binding Protein or IgE Binding Protein or Laminin Binding Protein or Mac 2 Antigen or LGALS3) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Galectin 3 (35 kDa Lectin or Carbohydrate Binding Protein 35 or Galactose Specific Lectin 3 or Galactoside Binding Protein or IgE Binding Protein or Laminin Binding Protein or Mac 2 Antigen or LGALS3) targeted therapeutics

REASONS TO BUY

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Galectin 3 (35 kDa Lectin or Carbohydrate Binding Protein 35 or Galactose Specific Lectin 3 or Galactoside Binding Protein or IgE Binding Protein or Laminin Binding Protein or Mac 2 Antigen or LGALS3)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Galectin 3 (35 kDa Lectin or Carbohydrate Binding Protein 35 or Galactose Specific Lectin 3 or Galactoside Binding Protein or IgE Binding Protein or Laminin Binding Protein or Mac 2 Antigen or LGALS3) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Contents

Introduction

Global Markets Direct Report Coverage

Galectin 3 (35 kDa Lectin or Carbohydrate Binding Protein 35 or Galactose Specific Lectin 3 or Galactoside Binding Protein or IgE Binding Protein or Laminin Binding Protein or Mac 2 Antigen or LGALS3) - Overview

Galectin 3 (35 kDa Lectin or Carbohydrate Binding Protein 35 or Galactose Specific Lectin 3 or Galactoside Binding Protein or IgE Binding Protein or Laminin Binding Protein or Mac 2 Antigen or LGALS3) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Galectin 3 (35 kDa Lectin or Carbohydrate Binding Protein 35 or Galactose Specific Lectin 3 or Galactoside Binding Protein or IgE Binding Protein or Laminin Binding Protein or Mac 2 Antigen or LGALS3) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Galectin 3 (35 kDa Lectin or Carbohydrate Binding Protein 35 or Galactose Specific Lectin 3 or Galactoside Binding Protein or IgE Binding Protein or Laminin Binding Protein or Mac 2 Antigen or LGALS3) - Companies Involved in Therapeutics Development

G3 Pharmaceuticals Inc

Galectin Therapeutics Inc

Galecto Biotech AB

Glycomantra Inc

GlycoMimetics Inc

Immutics Inc

MandalMed Inc

Proteris Biotech Inc

Galectin 3 (35 kDa Lectin or Carbohydrate Binding Protein 35 or Galactose Specific Lectin 3 or Galactoside Binding Protein or IgE Binding Protein or Laminin Binding Protein or Mac 2 Antigen or LGALS3) - Drug Profiles

belapectin - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GB-0139 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GB-1211 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GB-2064 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GM-101 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GM-200 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GMCT-04 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GMI-1757 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GRMD-03 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GRMD-04 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

IMT-001 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Protearin - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Recombinant Protein to Inhibit Galectin-3 for Myocardial Fibrosis and Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit Galectin-3 for Cardiovascular Disease, Fibrosis and Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit LGALS3 for Cardiovascular and Genito Urinary System Disorders - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TFD-100 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Galectin 3 (35 kDa Lectin or Carbohydrate Binding Protein 35 or Galactose Specific Lectin 3 or Galactoside Binding Protein or IgE Binding Protein or Laminin Binding Protein or Mac 2 Antigen or LGALS3) - Dormant Products

Galectin 3 (35 kDa Lectin or Carbohydrate Binding Protein 35 or Galactose Specific Lectin 3 or Galactoside Binding Protein or IgE Binding Protein or Laminin Binding Protein or Mac 2 Antigen or LGALS3) - Discontinued Products

Galectin 3 (35 kDa Lectin or Carbohydrate Binding Protein 35 or Galactose Specific Lectin 3 or Galactoside Binding Protein or IgE Binding Protein or Laminin Binding Protein or Mac 2 Antigen or LGALS3) - Product Development Milestones

Featured News & Press Releases

Feb 04, 2020: Galectin Therapeutics president and CEO Dr. Harold Shlevin to present at the 3rd Global NASH Congress 2020

Dec 09, 2019: Galectin Therapeutics phase 2 NASH cirrhosis clinical trial results on belapectin (GR-MD-02) published in gastroenterology

Dec 05, 2019: Galectin Therapeutics plans adaptively designed phase 3 NASH-RX

clinical trial in NASH Cirrhosis

Nov 11, 2019: Galectin Therapeutics reaches agreement with Siemens Healthineers to collaborate on NASH and Liver Fibrosis

Nov 05, 2019: Additional Ad Hoc analysis of ELF data from Galectin Therapeutics NASH-CX phase 2 clinical trial to be highlighted in poster presentation at the 2019 AASLD Liver Meeting

Sep 17, 2019: Galectin Therapeutics and Providence Cancer Institute receive patent on the use of Belapectin (GR-MD-02) in Cancer Immunotherapy

Aug 05, 2019: Galectin Therapeutics submits phase 3 NASH-RX protocol in Nash Cirrhosis to FDA

Mar 22, 2019: Providence Cancer Institute to Present Findings on GR-MD-02 at the 2019 Keystone Symposia on Molecular and Cellular Biology

Dec 04, 2018: GlycoMimetics presents poster at 60th ASH Annual Meeting highlighting preclinical data on GMI-1757

Nov 05, 2018: Data collected by Exalenz Bioscience in Galectin Therapeutics phase 2 NASH-CX trial of GR-MD-02 to be presented at AASLD Annual Meeting

Sep 20, 2018: Galectin Therapeutics announces positive preliminary results from phase 1b clinical trial of GR-MD-02 and KEYTRUDA in advanced melanoma and expansion of the Trial

Jul 18, 2018: GlycoMantra received SBIR Phase 1 grant from the NCI (NIH)

Jun 27, 2018: Galectin Therapeutics Receives Patent for GR-MD-02 Patent for Method and Treatment of Pulmonary Fibrosis

Jun 12, 2018: Galectin Therapeutics Announces New CEO

Jun 04, 2018: Galectin Therapeutics Announces Richard E. Uihlein Elected Chairman of the Board

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development by Stage of Development, H1 2020
Number of Products under Development by Therapy Areas, H1 2020
Number of Products under Development by Indications, H1 2020
Number of Products under Development by Indications, H1 2020 (Contd..1), H1 2020
Number of Products under Development by Companies, H1 2020
Products under Development by Companies, H1 2020
Products under Development by Companies, H1 2020 (Contd..1), H1 2020
Products under Development by Companies, H1 2020 (Contd..2), H1 2020
Number of Products by Stage and Mechanism of Actions, H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Pipeline by G3 Pharmaceuticals Inc, H1 2020
Pipeline by Galectin Therapeutics Inc, H1 2020
Pipeline by Galecto Biotech AB, H1 2020
Pipeline by Glycomantra Inc, H1 2020
Pipeline by GlycoMimetics Inc, H1 2020
Pipeline by Immutics Inc, H1 2020
Pipeline by MandalMed Inc, H1 2020
Pipeline by Proteris Biotech Inc, H1 2020
Dormant Products, H1 2020
Dormant Products, H1 2020 (Contd..1), H1 2020
Dormant Products, H1 2020 (Contd..2), H1 2020
Discontinued Products, H1 2020

List Of Figures

LIST OF FIGURES

Number of Products under Development by Stage of Development, H1 2020

Number of Products under Development by Therapy Areas, H1 2020

Number of Products under Development by Top 10 Indications, H1 2020

Number of Products by Stage and Mechanism of Actions, H1 2020

Number of Products by Routes of Administration, H1 2020

Number of Products by Stage and Routes of Administration, H1 2020

Number of Products by Molecule Types, H1 2020

Number of Products by Stage and Molecule Types, H1 2020

COMPANIES MENTIONED

G3 Pharmaceuticals Inc

Galectin Therapeutics Inc

Galecto Biotech AB

Glycomantra Inc

GlycoMimetics Inc

Immutics Inc

MandalMed Inc

Proteris Biotech Inc

I would like to order

Product name: Galectin 3 - Pipeline Review, H1 2020

Product link: <https://marketpublishers.com/r/G67412ED10EDEN.html>

Price: US\$ 3,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G67412ED10EDEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970